The rising problem of antimicrobial resistance in the intensive care unit

被引:0
作者
Nele Brusselaers
Dirk Vogelaers
Stijn Blot
机构
[1] Ghent University Hospital,Department of General Internal Medicine, Infectious Diseases, and Psychosomatic Medicine
[2] Ghent University,Faculty of Medicine and Health Sciences
[3] University College,undefined
来源
Annals of Intensive Care | / 1卷
关键词
Intensive Care Unit; Antimicrobial Resistance; Colistin; Clostridium Difficile; Vancomycin Resistance;
D O I
暂无
中图分类号
学科分类号
摘要
Mainly due to its extremely vulnerable population of critically ill patients, and the high use of (invasive) procedures, the intensive care unit (ICU) is the epicenter of infections. These infections are associated with an important rise in morbidity, mortality, and healthcare costs. The additional problem of multidrug-resistant pathogens boosts the adverse impact of infections in ICUs. Several factors influence the rapid spread of multidrug-resistant pathogens in the ICU, e.g., new mutations, selection of resistant strains, and suboptimal infection control. Among gram-positive organisms, the most important resistant microorganisms in the ICU are currently methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. In gram-negative bacteria, the resistance is mainly due to the rapid increase of extended-spectrum Beta-lactamases (ESBLs) in Klebsiella pneumonia, Escherichia coli, and Proteus species and high level third-generation cephalosporin Beta-lactamase resistance among Enterobacter spp. and Citrobacter spp., and multidrug resistance in Pseudomonas aeruginosa and Acinetobacter species. To conclude, additional efforts are needed in the future to slow down the emergence of antimicrobial resistance. Constant evaluation of current practice on basis of trends in MDR and antibiotic consumption patterns is essential to make progress in this problematic matter.
引用
收藏
相关论文
共 219 条
[1]  
Marwick C(2009)Care bundles: the holy grail of infectious risk management in hospital? Curr Opin Infect Dis 22 364-369
[2]  
Davey P(1999)Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups JAMA 281 67-71
[3]  
Hanberger H(1995)The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee JAMA 274 639-644
[4]  
Garcia-Rodriguez JA(2008)Daily cost of antimicrobial therapy in patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection Int J Antimicrob Agents 31 161-165
[5]  
Gobernado M(2008)Limiting the attributable mortality of nosocomial infection and multidrug resistance in intensive care units Clin Microbiol Infect 14 5-13
[6]  
Goossens H(2007)Measuring the impact of multidrug resistance in nosocomial infection Curr Opin Infect Dis 20 391-396
[7]  
Nilsson LE(2009)International study of the prevalence and outcomes of infection in intensive care units JAMA 302 2323-2329
[8]  
Struelens MJ(2005)Prevention and control of antimicrobial-resistant infections in intensive care patients Crit Care Med 33 2373-2382
[9]  
Vincent JL(2006)The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs Clin Infect Dis 42 S82-S89
[10]  
Bihari DJ(2008)Impact of antimicrobial resistance on the treatment and outcome of patients with sepsis Shock 30 23-29